Etigilimab
- Generic Name
- Etigilimab
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05715216
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1
Completed
- Conditions
- Solid Tumor, AdultMetastatic Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 76
- Registration Number
- NCT04761198
- Locations
- ๐บ๐ธ
Mereo Investigator Site, Fairfax, Virginia, United States
๐ฌ๐งRoyal Marsden, London, United Kingdom
๐ฌ๐งSarah Cannon UK, London, United Kingdom
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Locally Advanced CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03119428
- Locations
- ๐บ๐ธ
Oklahoma, Oklahoma City, Oklahoma, United States
๐บ๐ธNashville, Nashville, Tennessee, United States
๐บ๐ธDurham, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath